title: Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease.
abstract: OBJECTIVE
  To evaluate the clinical outcome and safety of adalimumab in patients with Vogt-Koyanagi-Harada (VKH) disease.
  
  
  METHODS
  VKH patients treated with adalimumab seen at the University of Buenos Aires were reviewed. Main outcome measures were visual acuity, anterior segment inflammation, optic nerve inflammation (ONI), steroid sparing effect, number of immunosuppressives, and relapses.
  
  
  RESULTS
  In total, 14 VKH patients, mean age 23.07 ± 8 years; median of adalimumab treatment 10 months, were analyzed. At start of adalimumab treatment (baseline), median of corticosteroid dose was 20 mg and at 6 months, 4 mg. At baseline, 11 patients were on immunosuppressive treatment and at 6 months only four continued with immunosuppressive therapy. In the 28 eyes, the median of active inflammation was 2 at baseline and 0 after 6 months on adalimumab.
  
  
  CONCLUSIONS
  Treatment with adalimumab is an effective and safe option, reducing the need for oral corticosteroid and conventional immunosuppressive therapy.
authors: a Uveitis Clinics, Department of Ophthalmology , University of Buenos Aires , Argentina.
authors: Cristóbal
authors: C
authors: Couto
authors: a Uveitis Clinics, Department of Ophthalmology , University of Buenos Aires , Argentina.
authors: Ariel
authors: A
authors: Schlaen
authors: a Uveitis Clinics, Department of Ophthalmology , University of Buenos Aires , Argentina.
authors: Mercedes
authors: M
authors: Frick
authors: a Uveitis Clinics, Department of Ophthalmology , University of Buenos Aires , Argentina.
authors: Marina
authors: M
authors: Khoury
authors: a Uveitis Clinics, Department of Ophthalmology , University of Buenos Aires , Argentina.
authors: Matilde
authors: M
authors: Lopez
authors: a Uveitis Clinics, Department of Ophthalmology , University of Buenos Aires , Argentina.
authors: Erika
authors: E
authors: Hurtado
authors: b Uveitis Service, Northwestern Memorial Hospital , Northwestern University , Chicago , Illinois , USA.
authors: Debra
authors: D
authors: Goldstein
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007165:Immunosuppression Therapy; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D012008:Recurrence; D014607:Uveomeningoencephalitic Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011239:Prednisolone; D000068879:Adalimumab
keywords: Adalimumab; Vogt–Koyanagi–Harada disease; chronic stage; clinical outcome; uveitis